Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

2.

The feasibility and acceptability of virtual environments in the treatment of childhood social anxiety disorder.

Sarver NW, Beidel DC, Spitalnick JS.

J Clin Child Adolesc Psychol. 2014;43(1):63-73. doi: 10.1080/15374416.2013.843461. Epub 2013 Oct 21.

3.

Management of asthma: new approaches to establishing control.

Sarver N, Murphy K.

J Am Acad Nurse Pract. 2009 Jan;21(1):54-65. doi: 10.1111/j.1745-7599.2008.00375.x. Review.

PMID:
19125896
4.

Circadian genes are expressed during early development in Xenopus laevis.

Curran KL, LaRue S, Bronson B, Solis J, Trow A, Sarver N, Zhu H.

PLoS One. 2008 Jul 23;3(7):e2749. doi: 10.1371/journal.pone.0002749.

5.

Asthma: helping patients breathe easier.

Murphy KR, Cecil B, Sarver NL.

Nurse Pract. 2004 Oct;29(10):38-55; quiz 55-7. Review. No abstract available.

PMID:
15489670
6.

Human immunodeficiency virus and AIDS: insights from animal lentiviruses.

Miller RJ, Cairns JS, Bridges S, Sarver N.

J Virol. 2000 Aug;74(16):7187-95. Review. No abstract available.

7.

Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648.

Chiang GG, Rubin HL, Cherington V, Wang T, Sobolewski J, McGrath CA, Gaffney A, Emami S, Sarver N, Levine PH, Greenberger JS, Hurwitz DR.

Hum Gene Ther. 1999 Jan 1;10(1):61-76.

PMID:
10022531
8.

New viral vectors for HIV vaccine delivery.

Cairns JS, Sarver N.

AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1501-8. Review. No abstract available.

PMID:
9840283
9.

HIV accessory proteins as therapeutic targets.

Miller RH, Sarver N.

Nat Med. 1997 Apr;3(4):389-94. Review. No abstract available.

PMID:
9095171
10.

Conference summary: novel HIV therapies--from discovery to clinical proof of concept.

Miller RH, Turk SR, Black RJ, Bridges S, Sarver N.

AIDS Res Hum Retroviruses. 1996 Jul 1;12(10):859-65.

PMID:
8798970
11.

Ribozyme trans-splicing and RNA tagging: following the messenger.

Sarver N, Cairns S.

Nat Med. 1996 Jun;2(6):641-2. No abstract available.

PMID:
8640553
12.

Gene therapy for HIV-1 infection.

Kohn DB, Sarver N.

Adv Exp Med Biol. 1996;394:421-8. Review. No abstract available.

PMID:
8815708
13.

HIV accessory proteins: emerging therapeutic targets.

Miller RH, Sarver N.

Mol Med. 1995 Jul;1(5):479-85. Review. No abstract available.

14.

Nucleic acid vaccines.

Vogel FR, Sarver N.

Clin Microbiol Rev. 1995 Jul;8(3):406-10. Review.

15.

Gene therapy and immune restoration for HIV disease.

Bridges SH, Sarver N.

Lancet. 1995 Feb 18;345(8947):427-32. Review. No abstract available.

PMID:
7853956
16.

Cellular distribution of HIV type 1 Nef protein: identification of domains in Nef required for association with membrane and detergent-insoluble cellular matrix.

Kaminchik J, Margalit R, Yaish S, Drummer H, Amit B, Sarver N, Gorecki M, Panet A.

AIDS Res Hum Retroviruses. 1994 Aug;10(8):1003-10.

PMID:
7811531
17.

Antisense catalytic RNAs as therapeutic agents.

Castanotto D, Rossi JJ, Sarver N.

Adv Pharmacol. 1994;25:289-317. Review. No abstract available.

PMID:
8204504
18.

Gene therapy: a bold direction for HIV-1 treatment.

Sarver N, Rossi J.

AIDS Res Hum Retroviruses. 1993 May;9(5):483-7. Review. No abstract available.

PMID:
8391287
19.

Ribozymes: use as anti-HIV therapeutic molecules.

Dropulic B, Elkins DA, Rossi JJ, Sarver N.

Antisense Res Dev. 1993 Spring;3(1):87-94. No abstract available.

PMID:
8495108
20.

Frontiers in HIV-1 Therapy: fourth conference of the NIAID National Cooperative Drug Discovery Groups-HIV.

Sarver N, Black RJ, Bridges S, Chrisey L.

AIDS Res Hum Retroviruses. 1992 May;8(5):659-67.

PMID:
1515217
21.

Molecular characterization of HIV1 Nef protein.

Kaminchik J, Sarver N, Gorecki M, Panet A.

Res Virol. 1992 Jan-Feb;143(1):50-2. No abstract available.

PMID:
1565857
22.

Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.

Rossi JJ, Sarver N.

Adv Exp Med Biol. 1992;312:95-109. Review. No abstract available.

PMID:
1514448
23.

EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain.

Hurwitz DR, Emanuel SL, Nathan MH, Sarver N, Ullrich A, Felder S, Lax I, Schlessinger J.

J Biol Chem. 1991 Nov 15;266(32):22035-43.

24.
25.

Meeting Report. Ribozymes: progress and prospects of catalytic RNA as therapeutic agents.

Chrisey L, Rossi J, Sarver N.

Antisense Res Dev. 1991 Spring;1(1):57-63. No abstract available.

PMID:
1822249
26.

Ribozymes: a new frontier in anti-HIV strategy.

Sarver N.

Antisense Res Dev. 1991 Winter;1(4):373-8. Review.

PMID:
1821659
27.

The potential use of catalytic RNAs in therapy of HIV infection and other diseases.

Rossi JJ, Cantin EM, Sarver N, Chang PF.

Pharmacol Ther. 1991;50(2):245-54. Review.

PMID:
1763136
28.

Expression and biochemical characterization of human immunodeficiency virus type 1 nef gene product.

Kaminchik J, Bashan N, Pinchasi D, Amit B, Sarver N, Johnston MI, Fischer M, Yavin Z, Gorecki M, Panet A.

J Virol. 1990 Jul;64(7):3447-54.

29.

RNA enzymes (ribozymes) as antiviral therapeutic agents.

Rossi JJ, Sarver N.

Trends Biotechnol. 1990 Jul;8(7):179-83. Review.

PMID:
1366622
30.

Ribozymes as potential anti-HIV-1 therapeutic agents.

Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ.

Science. 1990 Mar 9;247(4947):1222-5.

PMID:
2107573
31.

Ribozymes as therapies for AIDS.

Rossi JJ, Cantin EM, Zaia JA, Ladne PA, Chen J, Stephens DA, Sarver N, Chang PS.

Ann N Y Acad Sci. 1990;616:184-200. No abstract available.

PMID:
2078019
32.

Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications.

Rothenberg M, Johnson G, Laughlin C, Green I, Cradock J, Sarver N, Cohen JS.

J Natl Cancer Inst. 1989 Oct 18;81(20):1539-44. Review. No abstract available.

PMID:
2677394
33.

HIV proteinase as a target for drug action.

Johnston MI, Allaudeen HS, Sarver N.

Trends Pharmacol Sci. 1989 Aug;10(8):305-7. Review. No abstract available.

PMID:
2686126
34.
35.

Utilization of an Epstein-Barr virus replicon as a eukaryotic expression vector.

Young JM, Cheadle C, Foulke JS Jr, Drohan WN, Sarver N.

Gene. 1988;62(2):171-85.

PMID:
2835291
36.

Stable expression of recombinant factor VIII molecules using a bovine papillomavirus vector.

Sarver N, Ricca GA, Link J, Nathan MH, Newman J, Drohan WN.

DNA. 1987 Dec;6(6):553-64.

PMID:
2448100
37.

Optimizing gene expression in BPV-transformed cells: effects of cell type on enhancer/promoter interaction.

Hurwitz DR, Hodges R, Drohan W, Sarver N.

Nucleic Acids Res. 1987 Sep 11;15(17):7137-53.

38.

Enhancer-dependent expression of the rat preproinsulin gene in bovine papillomavirus type 1 vectors.

Sarver N, Muschel R, Byrne JC, Khoury G, Howley PM.

Mol Cell Biol. 1985 Dec;5(12):3507-16.

39.

Localization and analysis of bovine papillomavirus type 1 transforming functions.

Sarver N, Rabson MS, Yang YC, Byrne JC, Howley PM.

J Virol. 1984 Nov;52(2):377-88.

40.

Eukaryotic cloning vectors derived from bovine papillomavirus DNA.

Howley PM, Sarver N, Law MF.

Methods Enzymol. 1983;101:387-402. No abstract available.

PMID:
6310337
41.
42.

Bovine papilloma virus deoxyribonucleic acid: a novel eucaryotic cloning vector.

Sarver N, Gruss P, Law MF, Khoury G, Howley PM.

Mol Cell Biol. 1981 Jun;1(6):486-96.

43.

Virazole prevents production of Sindbis virus and virus-induced cytopathic effect in Aedes albopictus cells.

Sarver N, Stollar V.

Virology. 1978 Dec;91(2):267-82. No abstract available.

PMID:
741653
44.

Sindbis virus-induced cytopathic effect in clones of Aedes albopictus (Singh) cells.

Sarver N, Stollar V.

Virology. 1977 Jul 15;80(2):390-400. No abstract available.

PMID:
196393

Supplemental Content

Loading ...
Support Center